“We will continue to bring more capacity online in the second half of 2025 and expect our production capabilities to increase further.”

In context

“l of pirtobrutinib in CLL and SLL. And we launched the 2 highest doses of Zepbound in vials in the United States. We announced and closed the acquisition of SiteOne Therapeutics, which expands Lilly's pain portfolio and adds a clinical-stage non-opioid pain program to our mix. And Verve Therapeutics, which adds new genetic medicines for cardiovascular disease with potential to only be administered once in a person's lifetime. We made progress in Q2 and throughout the first half of 2025 to bring new manufacturing capacity online. We produced more than 1.6x the amount of salable incretin doses during the first half of 2025 when compared to the first half of 2024. This includes a significant step-up in capacity from our recently constructed facility in Research Triangle Park, North Carolina. We will continue to bring more capacity online in the second half of 2025 and expect our production capabilities to increase further. We also plan to announce the location of 2 of our new U.S. manufacturing facilities later this quarter. During the quarter, we distributed $1.3 billion in dividends and executed approximately $700 million in share repurchases. Before I turn the call over to Lucas, I'd like to offer some perspective on the drug pricing reform discussion that's going on. While we support the administration's position that medical research costs need to be shared more equitably across developed countries. It's also true that the U.S. pharmaceutical market has significant defects, which shift cost to consumers and increase red tape. These problems also require urgent reform and make apples-to-apples comparisons of ex-factory pricing inaccurate and misleading. At Lilly, we've already implemented several initia”